Shanghai Junshi Biosciences Co EBIT margin
Quel est le EBIT margin de Shanghai Junshi Biosciences Co?
Le EBIT margin de Shanghai Junshi Biosciences Co., Ltd. est -81.46%
Quelle est la définition de EBIT margin?
EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.
ttm (trailing twelve months)
EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.
EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.
EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.
EBIT margin des entreprises dans Health Care secteur sur OTC par rapport à Shanghai Junshi Biosciences Co
Que fait Shanghai Junshi Biosciences Co?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Entreprises avec ebit margin similaire à Shanghai Junshi Biosciences Co
- Alnylam Pharmaceuticals a EBIT margin de -82.32%
- Jernigan Capital a EBIT margin de -82.11%
- Asia-Pac Investment a EBIT margin de -81.91%
- Genetic Technologies a EBIT margin de -81.84%
- VBC Ferro Alloys a EBIT margin de -81.80%
- MICT Inc a EBIT margin de -81.54%
- Shanghai Junshi Biosciences Co a EBIT margin de -81.46%
- The McClatchy a EBIT margin de -80.94%
- Blue Blends (India) a EBIT margin de -80.91%
- Genius Brands International a EBIT margin de -80.90%
- Societe Francaise de Gestion et d'Investissement a EBIT margin de -80.81%
- Syncom Healthcare a EBIT margin de -80.80%
- Carebook Technologies a EBIT margin de -80.69%